Avalo Therapeutics, Inc. (AVTX) Financials
AVTX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 29.3 million | 14.6 million |
2023-06-30 | 24.2 million | 31.2 million |
2023-03-31 | 36.2 million | 42.5 million |
2022-12-31 | 33.4 million | 44.3 million |
AVTX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -6.8 million | 953000 |
2023-06-30 | -10.9 million | 893000 |
2023-03-31 | -10.2 million | 855000 |
2022-12-31 | -4.0 million | 843000 |
AVTX Net Income
No data available :(
AVTX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 10.2 million | - | 536000 |
2023-06-30 | 6.3 million | - | 535000 |
2023-03-31 | 16.7 million | 10.5 million | 533000 |
2022-12-31 | 13.2 million | - | 532000 |
AVTX Shares Outstanding
AVTX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | - | 1.2 million | 2.5 million | 7000 |
2023-06-30 | 158000 | 4.7 million | 2.4 million | 7000 |
2023-03-31 | 158000 | 6.0 million | 2.7 million | 13000 |
2022-12-31 | 56000 | 6.2 million | 2.9 million | 12000 |
AVTX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | 236000 | 247000 |
2023-06-30 | 643000 | 708000 |
2023-03-31 | 475000 | 551000 |
2022-12-31 | 896000 | 620000 |
AVTX
Price: $16
52 week price:
Earnings Per Share: -480.00 USD
P/E Ratio: -0.01
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 45800
Market Capitalization: 12.6 million